ClinicalTrials.gg
TerminatedNCT02601378Updated Sep 29, 2022

A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.

A Phase 1 interventional study of LXS196 and LXS196 and HDM201 in Uveal Melanoma, sponsored by Novartis Pharmaceuticals. Terminated at 6 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-29.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Why this study was terminated
The combination part of the study was terminated early due to business reasons

From the registry’s dates

  • Primary completion was Jan 2022, 4 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
107
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 190 studies in Uveal Melanoma with a site in United States — 25 open to participants now, 50 under way, 7 of them phase 3. Uveal Melanoma · United States.

Enrollment
26th of 162
107 · median 36
Started
2016
with 6 others
Phase 1
53 of 190
4 open now
Registered
101st of 190
by date

Among the 190 studies in Uveal Melanoma with a site in United States, this one is the 26th largest by enrollment of the 162 interventional ones that give a count, is one of 7 that started in 2016, is one of 53 in phase 1, and was the 101st registered.

Uveal Melanoma

281 studies on the registry are indexed under Uveal Melanoma; 50 are open to participants now.

Browse Uveal Melanoma studies →

Open to participants now

25 of the 190 studies in Uveal Melanoma with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 42 Uveal Melanoma studies recruiting now, 35 (83%) set no upper age limit and 4 (10%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 190 studies in Uveal Melanoma with a site in United States, or all of them as a file.
02

Study summary

This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent and in combination with HDM201 in patients with metastatic uveal melanoma.

03

Conditions studied

  • Uveal Melanoma

Browse trials for

Keywords

  • Uveal melanoma
  • Metastatic uveal melanoma
  • Phase I
  • LXS196
  • PKC inhibitor
  • HDM201
  • HDM2 inhibitor
  • dose escalation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female patients ≥18 years of age
  • Diagnosis of uveal melanoma with histological or cytological confirmed disease. Disease must be treatment naive or have progressed (radiologically or clinically) on most recent therapy.
  • Willingness to provide newly obtained tumor tissue at baseline and on treatment unless by medical risk in the opinion of the treating physician.
  • , defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm with conventional techniques or as >10 mm with CT scan.
  • performance status ≤ 1

Key Exclusion Criteria:

  • Malignant disease other than that being treated in this study.
  • Symptomatic or untreated or spinal cord compression. Brain metastasis must be stable with verification by imaging .
  • Impaired cardiac function or cardiac diseases
  • History of thromboembolic or cerebrovascular events within the last 6 months, including , cerebrovascular accident, deep vein thrombosis, or pulmonary embolism (applicable to combination part only).
  • Patients who are receiving treatment with medications that cannot be discontinued prior to study entry and that are considered to be any of the following:
  • known and possible risk for
  • known to be strong inducers or inhibitors of /5 (for single agent part); known to be moderate to strong inducers or inhibitors of CYP3A4/5 (for combination part)
  • known to be inducers or inhibitors of P-gp
  • known to be substrates of CYP3A4/5 and P-gp with a narrow therapeutic index
  • Patients with abnormal laboratory values, defined as any of the following:
  • or ALT > 3 times , AST or ALT > 5 times ULN for patients with liver metastases.
  • Total > 1.5 x ULN, except for patients with Gilbert's syndrome who are excluded if total bilirubin > 3.0 x ULN or direct bilirubin > 1.5 x ULN.
  • (ANC) ≤ 1.5 x109/L.
  • ≤ 100 x 109/L.
  • (Hgb) ≤ 90 g/L (9 g/dL).
  • Creatinine > 1.5 x ULN
  • Patients receiving due to the expected bone marrow toxicity (applicable to combination part only).
  • Patients treated with growth factors targeting the myeloid lineage (e.g. G-CSF, GM-CSF and M-CSF) within 2 weeks of starting study treatment. (applicable to combination part only).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    LXS196 as a single agent

    About 68 patients will be enrolled in dose escalation and expansion

    Drug: LXS196

  • Experimental
    LXS196 in combination with HDM201

    about 44 patients to be enrolled in dose escalation and expansion

    Drug: LXS196 and HDM201

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicities (DLTs) (Dose escalation only)

    cycle = 28 days

    Time frame: Cycle 1 in dose escalation

  2. Incidence and severity of adverse events and serious adverse events, including changes in laboratory parameters, vital signs and ECGs graded as per NCI CTCAE version 4.03 (All patients)

    Time frame: Continuously throughout the study until 30 days after treatment discontinuation

  3. Dose interruptions, reductions and dose intensity

    Time frame: Continuously throughout the study until 30 days after treatment discontinuation

Secondary outcomes

  1. Overall response rate (ORR) per RECIST version 1.1 criteria

    Time frame: From baseline, every 2 cycles until cycle 11, then every 3 cycles afterwards until disease progression or withdrawal of consent up to 12 months

  2. Plasma LXS196 concentration-time profiles as a single agent

    Time frame: Cycle 1 Day 1, 2, 3, 15; Cycle 2, 3, 4, 5 and 6 Day1

  3. Modulation of signaling molecules downstream of PKC

    Time frame: Baseline and Cycle 1 Day 15

  4. Progression free survival (PFS) per RECIST version 1.1 criteria

    Time frame: From baseline, every 2 cycles until cycle 11, then every 3 cycles afterwards until disease progression or withdrawal of consent up to 12 months

  5. Plasma PK parameters of LXS196 as a single agent:AUC

    Time frame: Cycle 1 Day 1, 2, 3, 15; Cycle 2, 3, 4, 5 and 6 Day1

  6. Plasma PK parameters of LXS196 as a single agent: Cmax

    Time frame: Cycle 1 Day 1, 2, 3, 15; Cycle 2, 3, 4, 5 and 6 Day1

  7. Plasma PK parameters of LXS196 as a single agent: Tmax

    Time frame: Cycle 1 Day 1, 2, 3, 15; Cycle 2, 3, 4, 5 and 6 Day1

  8. Plasma PK parameters of LXS196 as a single agent: t1/2

    Time frame: Cycle 1 Day 1, 2, 3, 15; Cycle 2, 3, 4, 5 and 6 Day1

  9. Plasma PK parameters of LXS196 as a single agent: Racc

    Time frame: Cycle 1 Day 1, 2, 3, 15; Cycle 2, 3, 4, 5 and 6 Day1

  10. Plasma HDM201 concentration-time profiles

    Time frame: Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day 1

  11. Plasma PK parameters of HDM201: AUC

    Time frame: Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day 1

  12. Plasma PK parameters of HDM201: Cmax

    Time frame: Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day 1

  13. Plasma PK parameters of HDM201: Tmax

    Time frame: Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day 1

  14. Plasma PK parameters of HDM201: t1/2

    Time frame: Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day 1

  15. Plasma LXS196 concentration-time profiles in combination with HDM201

    Time frame: Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day1

  16. Plasma PK parameters of LXS196 in combination with HDM201:AUC

    Time frame: Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day1

  17. Plasma PK parameters of LXS196 in combination with HDM201: Cmax

    Time frame: Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day1

  18. Plasma PK parameters of LXS196 in combination with HDM201: Tmax

    Time frame: Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day1

  19. Plasma PK parameters of LXS196 in combination with HDM201: t1/2

    Time frame: Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day1

  20. Plasma PK parameters of LXS196 in combination with HDM201: Racc

    Time frame: Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day1

  21. LXS196 plasma protein binding as a single agent

    Time frame: Cycle 1 Day 1, 2, 15, 16

  22. LXS196 plasma protein content as a single agent

    Time frame: Cycle 1, 2, 3 and 4 Day 1

07

Study locations

6 sites
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Novartis Investigative Site
    Westmead, New South Wales 2145, Australia
  • Novartis Investigative Site
    Paris, 75231, France
  • Novartis Investigative Site
    Leiden, 2300 RC, Netherlands
  • Novartis Investigative Site
    Oslo, 0379, Norway
  • Novartis Investigative Site
    Madrid, 28050, Spain
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2016 to primary completion in Jan 2022, 71 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2015
First posted
Nov 10, 2015
StartActual
Feb 1, 2016
Primary completionActual
Jan 7, 2022
CompletionActual
Jan 7, 2022
Last update
Sep 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02601378
Responsible party
Sponsor
First posted
Nov 10, 2015
Start date
Feb 1, 2016
Primary completion
Jan 7, 2022
Completion
Jan 7, 2022
Last update
Sep 29, 2022

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Darovasertib · Siremadlin

Start the discussion